Verrica Pharmaceuticals announced Phase 2 clinical data showing their drug VP-315 may trigger an abscopal effect, reducing untreated basal cell carcinoma (BCC) tumors beyond the injection site. This suggests VP-315 could activate the immune system broadly, potentially treating multiple BCC lesions and residual disease after surgery. The data showed an average 86% tumor size reduction and complete clearance in some untreated tumors, indicating a promising non-surgical option for BCC patients. Verrica will present these findings at the 2026 Society for Investigative Dermatology Annual Meeting, aiming to further validate VP-315's unique benefits.
Cortea secured €12 million in funding led by Dawn Capital to develop AI-powered Audit Quality Agents that review audit reports and financial statements, identifying errors and inconsistencies before sign-off. These tools help audit firms improve qual...
Cortea secured €12 million in seed funding led by Dawn Capital to develop AI tools that enhance audit quality without compromising accuracy. Their Audit Quality Agents review audit reports and financial statements to detect inconsistencies and errors...
Hong Kong Tourism Board has launched the "Hong Kong Summer Fun" campaign featuring a series of vibrant summer events including the 50th Sun Life Hong Kong International Dragon Boat Festival, Pixar Summer Fest, and a major football event with top Euro...
Hong Kong Tourism Board has launched the "Hong Kong Summer Fun" campaign, featuring festivals, family attractions, sports events, and exclusive summer deals valid until August 31. Highlights include the 50th Sun Life Hong Kong International Dragon Bo...
XTransfer has been recognized for the second consecutive year in FXC Intelligence’s 2026 Top 100 Cross-Border Payments Companies list, highlighting its role in advancing global B2B payment solutions. The company, serving over 890,000 enterprises in 2...
